NYSEARCA:PBE Invesco Biotechnology & Genome ETF (PBE) Price, Holdings, & News $84.10 0.00 (0.00%) As of 06/12/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock About Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PBE alerts:Sign Up Key Stats Today's Range$83.67▼$84.8950-Day Range$78.51▼$84.8252-Week Range$62.63▼$85.73Volume20,706 shsAverage Volume6,676 shsMarket Capitalization$261.55 millionAssets Under Management$261.88 millionDividend Yield1.02%Net Expense Ratio0.58%Aggregate RatingModerate Buy ETF Overview PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser. Read More Invesco Biotechnology & Genome ETF ExpensesTypePBEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.50%0.56%0.57%0.51%0.53%Other Expenses0.08%0.47%0.55%0.58%0.55%Total Expense0.58%0.74%0.76%0.74%0.73%Fee Waiver0.00%-0.71%-0.64%-0.70%-0.62%Net Expense0.58%0.59%0.63%0.58%0.60% Receive PBE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invesco Biotechnology & Genome ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBE ETF News HeadlinesInvesco Biotechnology & Genome ETF declares quarterly distribution of $0.0824March 24, 2026 | msn.comInvesco Biotechnology & Genome ETF declares quarterly distribution of $0.4197December 22, 2025 | seekingalpha.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 15 at 1:00 AM | Porter & Company (Ad)Invesco Nasdaq Biotechnology ETF declares quarterly distribution of $0.0958September 22, 2025 | msn.comInvesco Biotechnology & Genome ETF declares quarterly distribution of $0.2341September 22, 2025 | msn.comPBE Invesco Biotechnology & Genome ETFJanuary 29, 2025 | seekingalpha.comSee More Headlines PBE ETF - Frequently Asked Questions How have PBE shares performed this year? Invesco Biotechnology & Genome ETF's stock was trading at $82.15 at the start of the year. Since then, PBE shares have increased by 2.4% and is now trading at $84.10. Who are Invesco Biotechnology & Genome ETF's major shareholders? Top institutional shareholders of Invesco Biotechnology & Genome ETF include Royal Bank of Canada (1.91%), Bank of America Corp DE (1.91%), Cetera Investment Advisers (0.74%) and Kestra Advisory Services LLC (0.20%). How do I buy shares of Invesco Biotechnology & Genome ETF? Shares of PBE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Invesco Biotechnology & Genome ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invesco Biotechnology & Genome ETF investors own include Micron Technology (MU), Pfizer (PFE), Devon Energy (DVN), Intel (INTC), NVIDIA (NVDA) and Bristol Myers Squibb (BMY). Fund Details IssuerInvesco Fund NameInvesco Biotechnology & Genome ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:PBE Inception Date6/23/2005 Fund ManagerPeter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser Webwww.invescopowershares.com Phone+1-800-9830903Fund Focus Asset ClassEquity BenchmarkDynamic Biotech & Genome Intellidex Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings30 Fund Statistics Assets Under Management$261.88 million Average Daily Volume$5.21 thousand Discount/Premium0.07% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorInvesco Capital Management, LLC CustodianThe Bank of New York Mellon Corporation DistributorInvesco Distributors, Inc. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCitadel Options OptionableOptionable Options Volume2 Put Options1 Call Options1 Short Interest1,176 shs Miscellaneous Outstanding Shares3,110,000Beta0.72 Creation Unit10,000 Creation Fee$500.00 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report Top 10 PBE HoldingsIllumina (NASDAQ:ILMN)Holding Weight: 6.70%United Therapeutics (NASDAQ:UTHR)Holding Weight: 5.76%Biogen (NASDAQ:BIIB)Holding Weight: 4.93%Incyte (NASDAQ:INCY)Holding Weight: 4.74%Gilead Sciences (NASDAQ:GILD)Holding Weight: 4.45%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 4.44%Amgen (NASDAQ:AMGN)Holding Weight: 4.30%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 3.90%Veracyte (NASDAQ:VCYT)Holding Weight: 3.69%Catalyst Pharmaceuticals (NASDAQ:CPRX)Holding Weight: 3.53%Full Holdings DetailsPBE Sector ExposurePBE Industry Exposure This page (NYSEARCA:PBE) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Biotechnology & Genome ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PBE Stock Alerts